Candriam S.C.A. Boosts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Candriam S.C.A. boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 261,498 shares of the biopharmaceutical company’s stock after buying an additional 8,973 shares during the quarter. Regeneron Pharmaceuticals makes up about 1.1% of Candriam S.C.A.’s holdings, making the stock its 16th biggest position. Candriam S.C.A.’s holdings in Regeneron Pharmaceuticals were worth $186,273,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of the business. Howe & Rusling Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 3.4% during the 3rd quarter. Howe & Rusling Inc. now owns 462 shares of the biopharmaceutical company’s stock worth $486,000 after buying an additional 15 shares during the last quarter. Willner & Heller LLC increased its holdings in shares of Regeneron Pharmaceuticals by 3.9% during the 4th quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company’s stock worth $284,000 after buying an additional 15 shares during the last quarter. OLD Second National Bank of Aurora increased its holdings in shares of Regeneron Pharmaceuticals by 0.5% during the 4th quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company’s stock worth $2,025,000 after buying an additional 15 shares during the last quarter. Sigma Planning Corp increased its holdings in shares of Regeneron Pharmaceuticals by 4.1% during the 3rd quarter. Sigma Planning Corp now owns 409 shares of the biopharmaceutical company’s stock worth $430,000 after buying an additional 16 shares during the last quarter. Finally, GLOBALT Investments LLC GA increased its holdings in shares of Regeneron Pharmaceuticals by 1.5% during the 3rd quarter. GLOBALT Investments LLC GA now owns 1,067 shares of the biopharmaceutical company’s stock worth $1,122,000 after buying an additional 16 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Up 1.7 %

Regeneron Pharmaceuticals stock opened at $687.15 on Thursday. The company’s fifty day simple moving average is $696.58 and its 200-day simple moving average is $857.92. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $642.00 and a 12 month high of $1,211.20. The stock has a market cap of $75.12 billion, a P/E ratio of 17.95, a P/E/G ratio of 2.34 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $11.86 EPS. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.51%. Regeneron Pharmaceuticals’s dividend payout ratio is 2.30%.

Analyst Upgrades and Downgrades

REGN has been the subject of several recent research reports. Canaccord Genuity Group initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. Leerink Partners raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $762.00 to $834.00 in a research report on Wednesday, February 5th. Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. Citigroup reduced their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Finally, UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.